Search company, investor...

Blue Heron Biotech

blueheronbio.com

Founded Year

1999

Stage

Acquired - II | Acquired

Total Raised

$13.22M

About Blue Heron Biotech

Blue Heron Biotech delivers base pairs of genes to customers worldwide. Using its proprietary GeneMaker multi-technology platform, the company synthesizes nearly any gene. Blue Heron's gene synthesis capacity provides a whole product solution for the molecular biology research community.

Headquarters Location

22310 20th Avenue SE Suite 100

Bothell, Washington, 98021,

United States

888-368-5923

Missing: Blue Heron Biotech's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Blue Heron Biotech's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Blue Heron Biotech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Blue Heron Biotech is included in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

Blue Heron Biotech Patents

Blue Heron Biotech has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/13/2004

1/27/2009

Molecular biology, DNA, Biotechnology, Genetics, Molecular genetics

Grant

Application Date

10/13/2004

Grant Date

1/27/2009

Title

Related Topics

Molecular biology, DNA, Biotechnology, Genetics, Molecular genetics

Status

Grant

Blue Heron Biotech Frequently Asked Questions (FAQ)

  • When was Blue Heron Biotech founded?

    Blue Heron Biotech was founded in 1999.

  • Where is Blue Heron Biotech's headquarters?

    Blue Heron Biotech's headquarters is located at 22310 20th Avenue SE, Bothell.

  • What is Blue Heron Biotech's latest funding round?

    Blue Heron Biotech's latest funding round is Acquired - II.

  • How much did Blue Heron Biotech raise?

    Blue Heron Biotech raised a total of $13.22M.

  • Who are the investors of Blue Heron Biotech?

    Investors of Blue Heron Biotech include Eurofins Genomics, OriGene Technologies, Integra Ventures, Crabtree Ventures, Life Technologies Corporation and 4 more.

  • Who are Blue Heron Biotech's competitors?

    Competitors of Blue Heron Biotech include Sirnaomics, MOgene LC, ADV Bioscience, Agrisoma BioSciences, Biosceptre International and 13 more.

Compare Blue Heron Biotech to Competitors

Q
Qwell Pharmaceuticals

Qwell Pharmaceuticals is a biotechnology company focused on small molecule development primarily for oncology indications.

A
ADV Bioscience

ADV Bioscience is a biotechnology service company engaged in the application of self-developed, public domain technologies and licensed technologies primarily for gene discovery research and validation. The company's focus is offering these technologies primarily to the Chinese market.

P
ParentPlus

ParentPlus LLC was formed to alleviate male-factor subfertility by bringing biotechnology to millions of subfertile couples for whom intra-uterine insemination (IUI) might be an appropriate therapy. This therapy, with spousal or donor sperm, is underutilized perhaps in part because it frequently is neglected in the popular press. It is the company's belief that sperm from many subfertile men should be the target of a therapy based on modern biotechnology. Successful application of this concept could allow far more subfertile couples, when male-factor subfertility is a problem, to use IUI with spousal sperm to fulfill their dream of a having a baby. Hence, the focus of ParentPlus LLC is on reproductive media to enhance success primarily via IUI, but also enhancing IVF. In due course, demonstrated increased success rate with IUI using ParentPlus products will increase acceptance of IUI as the low cost alternative to highly publicized expensive treatments.

Bar Harbor BioTechnology Logo
Bar Harbor BioTechnology

Bar Harbor Biotech is a life sciences company spun-out from The Jackson Laboratory to develop gene expression products and services. Bar Harbor Biotech's technology focuses on real-time quantitative polymerase chain reaction (PCR), an established technique for gene expression used in disease research, molecular diagnostics, drug discovery, and other fields of biology research.

O
Orphagenix

OrphageniX is a drug development company aiming to develop therapeutics for genetic diseases using advancements in "Gene Editing" technologies. OrpageniX will focus on the low volume, high margin specialty pharmaceutical niche area of "Orphan Diseases" which are protected under the Orphan Drug Act (ODA). Per the company, the OrphageniX technology can be used for diagnostics and research tools. Gene Editing uses the cell's innate repair mechanisms to repair mutations that result in genetic diseases. According to OrphaageniX, it is similar to gene therapy but avoids the risks associated with a viral vector. It works like anti-sense and RNAi, but is more efficient and permanent within the repaired cell because it changes the gene itself and not the transient message. The company states that it has major collaborations with Yale Medical School, Albert Einstein Medical Center and the University of Washington.

Dicerna Pharmaceuticals Logo
Dicerna Pharmaceuticals

Dicerna Pharmaceuticals is a pharmaceutical company developing RNA interference (RNAi)-based therapeutics against genetically-defined targets in multiple disease areas, including cancer. Dicerna's therapeutic approach utilizes its Dicer Substrate siRNA (DsiRNA) molecules and EnCore drug delivery technologies to silence previously undruggable disease targets, offering a potential new treatment option for patients. Dicerna delivers its DsiRNA molecules to cancer cells using its EnCore lipid nanoparticle drug delivery technology. EnCore has been specifically engineered to accumulate in tumors and mediate efficient delivery of the DsiRNAs to the RNAi machinery in the cancer cell cytoplasm. Encore particles are well tolerated and manufactured using well-established unit operations to ensure commercial scalability.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.